Trial
NCT02277522
CD19 Redirected Autologous T Cells for Hodgkin Lymphoma
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Pennsylvania
Collaborators
—
Condition
Hodgkin Lymphoma With no Available Curative Treatment Options Who Have a Limited Prognosis
Intervention
RNA anti-CD19 CAR T cells
Why stopped
unable to meet enrollment goal
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-06-22